NO20011116D0 - Anvendelse av metoksymorfolinodoksorubicin for behandling av levertumor - Google Patents

Anvendelse av metoksymorfolinodoksorubicin for behandling av levertumor

Info

Publication number
NO20011116D0
NO20011116D0 NO20011116A NO20011116A NO20011116D0 NO 20011116 D0 NO20011116 D0 NO 20011116D0 NO 20011116 A NO20011116 A NO 20011116A NO 20011116 A NO20011116 A NO 20011116A NO 20011116 D0 NO20011116 D0 NO 20011116D0
Authority
NO
Norway
Prior art keywords
liver tumor
treatment
methoxymorpholinodoxorubicin
liver
methoxymorpholino doxorubicin
Prior art date
Application number
NO20011116A
Other languages
English (en)
Other versions
NO329746B1 (no
NO20011116L (no
Inventor
Maria Adele Pacciarini
Olga Valota
David Kerr
Original Assignee
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa
Publication of NO20011116D0 publication Critical patent/NO20011116D0/no
Publication of NO20011116L publication Critical patent/NO20011116L/no
Publication of NO329746B1 publication Critical patent/NO329746B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20011116A 1998-09-14 2001-03-05 Anvendelse av metoksymorfolinodoksorubicin for behandling av levertumor og en farmasoytisk sammensetning inneholdende denne NO329746B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9820012.4A GB9820012D0 (en) 1998-09-14 1998-09-14 Use of an anthracycline derivative for the treatment of a liver tumor
PCT/EP1999/006298 WO2000015203A2 (en) 1998-09-14 1999-08-27 Use of methoxymorpholino doxorubicin for the treatment of a liver tumor

Publications (3)

Publication Number Publication Date
NO20011116D0 true NO20011116D0 (no) 2001-03-05
NO20011116L NO20011116L (no) 2001-05-14
NO329746B1 NO329746B1 (no) 2010-12-13

Family

ID=10838847

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20011116A NO329746B1 (no) 1998-09-14 2001-03-05 Anvendelse av metoksymorfolinodoksorubicin for behandling av levertumor og en farmasoytisk sammensetning inneholdende denne

Country Status (26)

Country Link
EP (1) EP1112066B1 (no)
JP (2) JP5529360B2 (no)
KR (1) KR100685155B1 (no)
CN (1) CN1168452C (no)
AT (1) ATE245029T1 (no)
AU (1) AU773451B2 (no)
BR (1) BR9913627A (no)
CA (1) CA2343120C (no)
CZ (1) CZ295901B6 (no)
DE (1) DE69909636T2 (no)
DK (1) DK1112066T3 (no)
EA (1) EA004570B1 (no)
ES (1) ES2203175T3 (no)
GB (1) GB9820012D0 (no)
HK (1) HK1050853A1 (no)
HU (1) HU229186B1 (no)
ID (1) ID28035A (no)
IL (2) IL141645A0 (no)
MY (1) MY124247A (no)
NO (1) NO329746B1 (no)
NZ (1) NZ510445A (no)
PL (1) PL198025B1 (no)
PT (1) PT1112066E (no)
TW (1) TWI222868B (no)
UA (1) UA69423C2 (no)
WO (1) WO2000015203A2 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9909925D0 (en) 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
US20060183168A1 (en) * 2002-10-28 2006-08-17 Geroni Maria C Method for optimizing therapeutic efficacy of nemorubicin
DE602004007491T2 (de) * 2003-02-26 2008-03-13 Nerviano Medical Sciences S.R.L., Nerviano Verfahren zur behandlung von leberkrebs durch intrahepatische verabreichung von nemorubicin
WO2008138758A1 (en) * 2007-05-11 2008-11-20 Nerviano Medical Sciences S.R.L. Pharmaceutical composition of an anthracycline
JP2016124818A (ja) * 2014-12-26 2016-07-11 日本化薬株式会社 転移性肝癌治療薬及び転移性肝癌の治療方法
PL244818B1 (pl) * 2021-11-03 2024-03-11 Urteste Spolka Z Ograniczona Odpowiedzialnoscia Związek-marker diagnostyczny raka wątroby, sposób wykrywania aktywności enzymatycznej, sposób diagnozowania raka wątroby, zestaw zawierający taki związek oraz związek do zastosowania medycznego

Also Published As

Publication number Publication date
MY124247A (en) 2006-06-30
DE69909636T2 (de) 2004-06-09
CN1168452C (zh) 2004-09-29
EA200100353A1 (ru) 2001-10-22
GB9820012D0 (en) 1998-11-04
CA2343120C (en) 2009-11-24
ATE245029T1 (de) 2003-08-15
ES2203175T3 (es) 2004-04-01
EA004570B1 (ru) 2004-06-24
CA2343120A1 (en) 2000-03-23
NO329746B1 (no) 2010-12-13
IL141645A (en) 2007-05-15
WO2000015203A3 (en) 2000-07-20
JP5529360B2 (ja) 2014-06-25
CZ2001895A3 (cs) 2001-08-15
HUP0103557A3 (en) 2002-12-28
WO2000015203A2 (en) 2000-03-23
IL141645A0 (en) 2002-03-10
JP2014088398A (ja) 2014-05-15
JP2002524496A (ja) 2002-08-06
HU229186B1 (en) 2013-09-30
CZ295901B6 (cs) 2005-11-16
HK1050853A1 (en) 2003-07-11
KR100685155B1 (ko) 2007-02-22
NZ510445A (en) 2003-01-31
DK1112066T3 (da) 2003-11-03
PL348749A1 (en) 2002-06-03
UA69423C2 (uk) 2004-09-15
AU773451B2 (en) 2004-05-27
EP1112066B1 (en) 2003-07-16
ID28035A (id) 2001-05-03
TWI222868B (en) 2004-11-01
NO20011116L (no) 2001-05-14
KR20010075074A (ko) 2001-08-09
AU5742199A (en) 2000-04-03
HUP0103557A2 (hu) 2002-01-28
BR9913627A (pt) 2001-05-22
EP1112066A2 (en) 2001-07-04
PL198025B1 (pl) 2008-05-30
PT1112066E (pt) 2003-11-28
CN1383382A (zh) 2002-12-04
DE69909636D1 (de) 2003-08-21

Similar Documents

Publication Publication Date Title
MXPA02010801A (es) Agentes diagnosticos, de representacion y terapeuticos cationicos asociados con sitios vasculares activados.
EA200100111A1 (ru) Ингибиторы фарнезилпротеинтрансферазы, обладающие in vivo радиосенсибилизирующими свойствами
WO2002046477A3 (en) Endogenous retroviruses up-regulated in prostate cancer
IT1309583B1 (it) Catetere perfezionato per interventi vascolari.
WO2002029103A3 (en) Gene expression profiles in liver cancer
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
UY26456A1 (es) Compuestos que fijan la estructura g-cuadruplex de los telomeros, triazinas de aplicación de dichos compuestos, la utilización de dichos compuestos como productos farmacéuticos y las asociaciones terapéuticas que los incluyen.
GT200400242A (es) Uso extendido de combinacion que comprende estrogenos y progestina.
AR027355A1 (es) Acidos tiazolidincarboxilicos
CY1110329T1 (el) Πεγκυλιωμενη λιποσωμιακη δοξορουβικινη σε συνδυασμο με εκτεϊνασκιδινη 743
NO985917L (no) Reduksjon av kardiotoksisitet til antitumormiddel ved bruk av manganforbindelse
AR023616A1 (es) Preparaciones combinadas que comprenden derivados de antraciclina
MY137766A (en) Exemestane as chemopreventing agent
AR021750A1 (es) Aparato para el tratamiento topico localizado de una enfermedad
NO20011116D0 (no) Anvendelse av metoksymorfolinodoksorubicin for behandling av levertumor
WO2000013712A3 (en) Methods and compositions for the prevention or treatment of cancer
NO20015338D0 (no) Androgenderivater og anvendelse derav
DK1124566T3 (da) Ikke-fermenteret osmotisk laxativ til behandling og forebyggelse af colorectale cancere
BR0014192A (pt) Conjugados de corantes e anticorpos contra estruturas-alvo da angiogênese, para representação intra-operativa da margem de tumores
BRPI0510062A (pt) derivados de antraciclina
EP1234585A3 (en) Methods and compositions for the prevention or treatment of cancer
AR027677A1 (es) Una composicion farmaceutica terapeutica que comprende camptotecina y ciclofosfamida para el tratamiento del cancer
CO5170459A1 (es) Terapia transdermica con agonistas-antagonistas de estrogenos len-ol, administrados mediante medios transdermicos
BR0306809A (pt) Sistema terapêutico para o tratamento de tumores, método de tratamento de um tumor, e, uso de uma combinação de um anticorpo radiomarcado e um agente quimioterapêutico
UY27211A1 (es) Derivados químicos y su aplicación como agente antitelomerasa

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees